Virpax Price Book Value Ratio from 2010 to 2024

VRPX Stock  USD 0.57  0.02  3.39%   
Virpax Pharmaceuticals Price Book Value Ratio yearly trend continues to be fairly stable with very little volatility. Price Book Value Ratio is likely to outpace its year average in 2024. During the period from 2010 to 2024, Virpax Pharmaceuticals Price Book Value Ratio regression line of annual values had significance of  0.000047 and arithmetic mean of (163.42). View All Fundamentals
 
Price Book Value Ratio  
First Reported
2010-12-31
Previous Quarter
1.9376027
Current Value
2.03
Quarterly Volatility
136.10195637
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Virpax Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Virpax Pharmaceuticals' main balance sheet or income statement drivers, such as Tax Provision of 0.0, Net Interest Income of 988 or Interest Expense of 126.5 K, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 2.03. Virpax financial statements analysis is a perfect complement when working with Virpax Pharmaceuticals Valuation or Volatility modules.
  
Check out the analysis of Virpax Pharmaceuticals Correlation against competitors.
For more information on how to buy Virpax Stock please use our How to Invest in Virpax Pharmaceuticals guide.

Latest Virpax Pharmaceuticals' Price Book Value Ratio Growth Pattern

Below is the plot of the Price Book Value Ratio of Virpax Pharmaceuticals over the last few years. It is Virpax Pharmaceuticals' Price Book Value Ratio historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Virpax Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
Price Book Value Ratio10 Years Trend
Slightly volatile
   Price Book Value Ratio   
       Timeline  

Virpax Price Book Value Ratio Regression Statistics

Arithmetic Mean(163.42)
Coefficient Of Variation(83.28)
Mean Deviation128.78
Median(270.74)
Standard Deviation136.10
Sample Variance18,524
Range273
R-Value0.86
Mean Square Error5,331
R-Squared0.73
Significance0.000047
Slope26.05
Total Sum of Squares259,332

Virpax Price Book Value Ratio History

2024 2.03
2023 1.94
2022 0.44
2021 1.07
2020 -7.66
2019 -12.46

About Virpax Pharmaceuticals Financial Statements

Virpax Pharmaceuticals investors use historical fundamental indicators, such as Virpax Pharmaceuticals' Price Book Value Ratio, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Virpax Pharmaceuticals. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Price Book Value Ratio 1.94  2.03 

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Virpax Stock Analysis

When running Virpax Pharmaceuticals' price analysis, check to measure Virpax Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Virpax Pharmaceuticals is operating at the current time. Most of Virpax Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Virpax Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Virpax Pharmaceuticals' price. Additionally, you may evaluate how the addition of Virpax Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.